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Introduction
Reflecting the fact that regulatory agencies recently
required companies to initiate a pediatric drug develop-
ment plan earlier in the drug development sequence for
compounds first developed for adults, most psychiatric
drugs for children still remain the offspring of adult
drug development programs, viz., except for the psy-
chostimulants, very few psychiatric medications have
been developed for children and adolescents by first
intent [1]. However, two irreversible trends are gradually
shifting intervention development for psychiatric disor-
ders away from a focus on adult organisms to a focus
on developing organisms. First, epidemiological data
indicate that the great majority of mentally ill adults
were first mentally ill as children [2], and that this effect
is evident as early as two years of age [3]. Second, recent
advances in translational developmental neuroscience
have shown that mental illness of all types can be refer-
enced directly to the developing central nervous system
and its interactions with the environment [4]. The
knowledge that mental disorders are early onset, trajec-
tory-based brain illnesses has enormous implications for
the nature and organization of how we understand
interventions for psychiatric patients of all ages [5,6].
Put succinctly, to preempt, prevent and cure psychiatric
disorders, it will be necessary to translate insights about
molecular pathways for mental illness into druggable
targets that directly reflect key neurodevelopmental pro-
cesses that form trajectories of atypical as contrasted to
typical development [7]. To this end, this commentary
will describe drug development in pediatric psychiatry
with reference to three converging perspectives: funda-
mental biology and target identification, early phase
clinical pharmacology, and the importance of biomar-
kers in the shift to personalized medicine.
Discussion
Fundamental Biology and Target Identification
As shown in Table 1 drug development ideally follows a
series of well-recognized steps: understanding disease-
specific cellular and molecular pathobiology; target iden-
tification and assay development; identification and opti-
mization of a lead molecule; toxicology and
manufacturing; and eventually a series of investigational
new drug (IND) trials that are expected to lead to a suc-
cessful New Drug Application (NDA). While there are a
variety of incentives and requirements that differentiate
pediatric from adult drug development in psychiatry (for
reviews, see [8,9]), the key point for our purposes is that
a rich understanding of molecular driver (primary to off
trajectory development) and modulatory pathways will
reveal potentially druggable targets as well as diagnostic
and response biomarkers that will proceed through the
drug development process together. In a striking exam-
ple from cancer biology, gefitinib, a biologic (an anti-
body as contrasted to a small molecule) that antagonizes
the receptor for epidermal growth factor (EGFR), is a
potent treatment for non-small cell lung cancer
(NSCLC), but only in those patients with a particular
genetic form of EGFR [10]. In the cancer model, a small
number of commonly mutated gene “mountains” and a
much larger number of gene “hills” that are mutated at
low frequency comprise the driver pathways for onco-
genesis [11,12]. If neuropsychiatric disorders follow the
cancer model–and it appears from studies in autism,
schizophrenia, bipolar disorder and epilepsy that this
may be the case [13-15]–progress in understanding the
nature and heterogeneity of complex psychiatric diseases
should presage the development of targeted disease
modifying treatments for psychiatric disorders [16].
Until psychiatric genetics yields validated targets or
even clinically efficacious stratification markers for the
major classes of psychiatric illness [17], the approach to
drug development in psychiatry will remain where it
always has been, namely opportunistic rather than
mechanistic. In the past and to some extent today, drug
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development in psychiatry deviated from step one in
that serendipity usually based on clinical observation
lead to small proof of principle trials, animal studies,
and then to rational medical chemistry efforts [18], viz.
the progression from imipramine to fluoxetine. In fact,
other than lithium [19], many if not most current gen-
eration antipsychotics and antidepressants have chlor-
promazine as the root molecule, with modifications
based on clinical insights like the fact that chlorproma-
zine itself has antidepressant as well as antipsychotic
effects [20]. Some argue that opportunistic insights will
remain the primary route for new medicines in psychia-
try for the next decade or more [18]; others claim that
the tremendous investment in fundamental biology on
the part of industry and the NIH shortly will begin to
pay off in new, innovative, disease state therapeutics
[21]. In favor of the latter are newly identified therapeu-
tics that target three mechanistically distinct glutamate
pathways: First, intraveneous ketamine produces promis-
ing and rapid antidepressant effects in treatment resis-
tant depression (for review see [22]). This finding, which
seems to involve rapid effects on synaptogenesis pre-
sumably via brain derived neurotrophic factor (BDNF),
TrkB and mTOR pathways [23], has generated consider-
able interest in orally available N-methyl-D-aspartate
antagonists and AMPA receptor potentiators as treat-
ments for depression [24]. Second, selective agonists for
metabotropic glutamate 2/3 (mGlu2/3) receptors that
show antipsychotic potential in animal models of schizo-
phrenia [25] show promise in clinical trials in patients
with schizophrenia [26]. And third, genetic insightsinto
the molecular pathobiology of Fragile X syndrome have
lead to the development of a class of compounds, the
mGluR5 antagonists, that reverse the Fragile X pheno-
type in animal models of Fragile X [27]. Trials in
humans are just now getting underway [27,28]. If suc-
cessful, Fragile X will be the first psychiatric disorder in
which a potentially curative treatment was developed
mechanistically from gene identification to pathophysiol-
ogy in animal models to novel therapeutics in humans.
For neurodevelopmental targets–the only possible tar-
gets that are preemptive–that exhibit complex rather
than Mendelian genetics, the identification of persona-
lized drugable targets on driver pathways is particularly
challenging [4,29,30]. As shown in Figure 1, the pro-
cesses that go awry in mental illness likely involve time-
sensitive modulation in gene expression, cellular interac-
tions, circuit formation and function, and behavior, all
interacting alongside environmental experience to pro-
duce typical or atypical developmental trajectories
[31,32]. Moreover, the onset of symptoms may not indi-
cate the actual beginning of the illness, e.g. symptoms
may appear long after the causal processes leading to
mental illness have begun (see, for example, DISC1 and
schizophrenia [13]). Acute or downstream, these pro-
cesses necessarily will become the targets for interven-
tions that aim to restore normal developmental process
or to initiate compensatory processes that return a
patient to a functional neurodevelopmental trajectory
[7,33]. In each case, points of leverage (drugable targets)
utilizing small molecules, biologics, RNA or protein
aptamers targeting pre- or post-synaptic receptors or
intracellular signal transduction pathways will only
emerge when the relevant disease-specific molecular
Table 1 Steps in Drug Development
Discovery and Concept Development
• Target Identification and Validation
• Assay Development and Screening
• Lead Molecule Discovery
• Lead Molecule Optimization
• Pharmacodynamics and Toxicology
Proof of Concept/IND
• Clinical Phase I: PK/PD, ADME, abuse liability
• Phase II Proof of Concept
Product Development
• Phase III Registration
• NDA Approval
• Phase IV Post Marketing
Figure 1 Translational Developmental Neuroscience. depicts the
time course of atypical versus typical development. The red arrow
at in early childhood indicates a perturbation followed by an
immediate or later onset trajectory deviation involving dynamic
changes in molecular systems, information processes running on
hierarchically distributed neural networks, and resulting
psychopathology, which when sufficiently altered (brown circle)
comes to clinical attention. Opportunities for preemption predate
the onset of clinical illness either before or early in the prodromal
period of delayed development.
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pathways are clarified allowing disease relevant targets
to be distinguished from relatively common pathways
that are involved in basic cell functions and, thus, in
both normal and disease states, viz. the mTOR pathway
in autism [34]. Despite the difficulty of the task–and it
is indeed humbling–the availability of personal genomic
and a wealth of large-scale biological datasets provide an
unprecedented opportunity to identify therapeutically
relevant targets that will be both druggable and disease
modifying [35].
Emphasizing the importance of developmental neu-
roscience to understanding the fundamental biology of
mental illness, a 2008 National Advisory Mental Health
Council (NAMHC) Workgroup (co-chaired by John
March and Pat Levitt) issued a report entitled Transfor-
mative Neurodevelopmental Research In Mental Illness
that strongly recommended that the NIMH refocus its
discovery and translational neuroscience portfiolio on
identifying and translating testable developmental tar-
gets into new preemption and treatment efforts. On the
other hand, while tools and technologies, such as the
ability to define the patterns of gene expression and
manipulate the major pathways for signal transduction
in brain subregions as they impact early development,
now permit interrogating the CNS in model organisms
[36] or in induced pluripotent stem cells [37], the trans-
lational payoff in preventive pediatric indications is
years and perhaps even decades away [38-40]. In the
meantime, as illustrated by the attempts to intervene in
prodromal schizophrenia [41,42], improved disease state
therapeutics that involve early intervention in the illness
prodrome or early in its course will increasingly come
to dominate psychiatric therapeutics.
The Shift to Early Phase Clinical Pharmacology
In addition to the promising impact of improved target
identification, the shift toward early phase clinical phar-
macology, is also being driven by a variety of other fac-
tors, including high costs, an empty pipeline, success
rates that are lower for neuroscience trials that in any
other therapeutic area, competition with generics, and
the need to satisfy not only the FDA but payers regard-
ing a treatments incremental value. Consequently, some
companies have pulled out of psychiatry R&D altogether
[36,43] and others are downsizing, preferring to wait
until improvement in our understanding of fundamental
biology generates novel drugable targets that can be
move through the preclinical drug development process
and eventually into early phase clinical trials programs
[21]. Given the need to substantially increase the num-
ber and quality of innovative, cost-effective new medi-
cines without incurring unsustainable R&D costs, Paul
and colleagues recently recommended a shift in empha-
sis from large and expensive Phase III programs to a
focus on multiple “quick win, quick fail” proof of con-
cept (POC) trials [43]. The central idea is to promote to
Phase III only those compounds that have a high prob-
ability of success as indicated by the results of a care-
fully executed Phase II program.
Since the impetus for developing novel therapeutics is
frequently dependent on work in academic laboratories
or in biotech or small pharma “spinoffs” from academia
[44,45], it is likely that the development process for new
molecules that enter POC increasingly will depend on
collaborations between industry, the NIH and academic
medical centers [21,46,47]. In this context, Tom Insel,
the current NIMH Director, recently articulated a strate-
gic plan for the NIMH that emphasizes the importance
of novel interventions that emerge from the NIMH’s
investment in discovery and translational neuroscience
[6]. The enduring vision is to explicate the underlying
neurobiology, identify new treatment targets, develop
drugs, biologics, devices and refined psychosocial inter-
ventions for new targets, and do so in a lifespan context
that emphasizes early developmental events and is per-
sonalized. To lay the foundation for developing the next
generation of interventions for mental disorders, espe-
cially those interventions that are tailored to the indivi-
dual (i.e., that are personalized) and that prevent the
damaging consequences of these illnesses (i.e., that are
preemptive), the NAMHC (David Lewis and John
March, co-chairs) recently issued a report, From Discov-
ery to Cure [48], that provides explicit guidance regard-
ing promising research investments and strategies.
Capitalizing on key NIH investments in technologies for
the development of novel therapeutics [21,47,49], the
workgroup reports puts in place a smooth and efficient
process for intervention discovery, from pre-clinical stu-
dies to Phase I safety and dose finding studies in typical
humans through proof-of-concept Phase II studies, and
the establishment of clinical efficacy. Consequently, the
NIMH also is moving away from studying current gen-
eration treatments and toward early phase intervention
development [48]. Importantly, while pediatric drug
development programs will continue to follow adult
intervention development [29], the NIMH is now turn-
ing toward building a knowledge environment in which
mentally ill youth are viewed as a key target population.
Biomarkers and the Shift to Personalized Medicine
Biomarkers, which emerge from the process of target
identification, are the foundation of stratified and even-
tually personalized diagnosis and treatment. Stratified
medicine means using biomarkers to tailor health care
to a group of patients with similar characteristics; perso-
nalized medicine refers to using biomarkers to tailor
health care to the needs of the individual patient.
According to a recent IOM report on neuroscience
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biomarkers[50], biomarkers are clinically applicable
quantitative measurements about biological processes, a
disease state, or about response to treatment. A bio-
signature is a collection of biomarkers optimized for
predictive validity. “-Omics” biomarkers refer to the
contribution of genes, proteins, and metabolic pathways
to human physiology and to the fact that variations
along -omics pathways are thought to lead to disease
vulnerability. Specific -omics technologies (often called
platforms) include genetics/genomics, epigenetics, trans-
ciptomics, proteomics and metabolomics. Neuroimaging
biomarkers include MRI, PET, QEEG and MEG, and
can be combined with -omics markers to increase preci-
sion in systems biological approach that examines the
interactions between the diverse aspects of biological
systems as they give rise to organismal behaviors in
health and in diseases [51,52]. A biomarker generally
provides one of two kinds of information: diagnostic or
therapeutic. Using FDA/industry terminology therapeu-
tic biomarkers are referred to as companion (to treat-
ment) diagnostics that do one of the following: stratify
patients on choice of treatment, tailor the dose of treat-
ment, predict response early in treatment, or provide a
surrogate endpoint to facilitate the study of intervention
efficacy.
While the FDA has released guidance documents on
validating biomarker/biosignatures,[53,54] there is still
considerable confusion in our field over what is required
to identify, validate and apply a new test in clinical set-
tings[55,56] so much so that the AACAP Research
Forum at the 2011 annual meeting in Toronto was
devoted to explicating biomarker sciences. In an innova-
tive example of biomarker based therapeutics in a pub-
lic-private partnership framework [57], the Foundation
for the NIH (FNIH) is sponsoring biomarker stratified
adaptive RCTs in advanced breast cancer, the Investiga-
tion of Serial Studies to Predict Your Therapeutic
Response (I-SPY) studies, that use the patient’s own
tumor tissue and a commercially available gene chip,
the MammaChip, to improve treatment outcomes in by
using a companion diagnostic to identify the best treat-
ment strategy at each point in disease progression, e.g.
to apply stratified medical strategies to personalize care
[58]. In psychiatry, Alzheimer’s disease provides a very
useful model for understanding how to think about
early intervention for a trajectory-based neurodevelop-
mental disorder [59]. In a series of papers [60-62], the
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
with funding from the FNIH and industry has promoted
the development of CSF proteomic, fMRI and PET bio-
markers that accurately track the progression from nor-
mal elderly to mild cognitive impairment (MCI) to
Alzheimer’s disease (AD). Understanding the progres-
sion of AD biology over time has enabled the
identification of disease and response biomarkers as well
as surrogate endpoints for clinical trials. In turn, this
has facilitated the development of disease-modifying
treatments like the humanized anti-Abeta monoclonal
antibody, bapineuzumab, that is currently undergoing
Phase III clinical trials [63]). The point here is not that
bapineuzumab by itself is going to transform the lives of
patients with Alzheimer’s Disease–it faces a variety of
hurdles [64]-but rather that the availability of, for exam-
ple, a PET biomarker allows medicines to be given
much earlier in the disease course thereby offering the
potential of disease modification. Given the obvious par-
allels, we might expect that conceptual models derived
from AD should positively influence drug development
programs for neurodevelopmental disorders at the other
end of the age spectrum.
Ethical considerations and need for new trial regulations
Future psychopharmacological interventions will aim at
identifying targets to predict distal outcomes. The iden-
tification of a certain risk in the context - for example
of a screening procedure in early childhood - might lead
to preventive therapeutic interventions to prevent, for
example, schizophrenia [42], or even Alzheimer’s Dis-
ease [65]. Psychiatrists now try to describe schizophrenia
prodrome as a disorder based on descriptive symptoms.
If schizophrenia prodrome would be introduced as a
disorder, on intervening in prodromal schizophrenia this
disorder could be an indication in the context of current
drug regulations. In McGorry’s seminal study of inter-
vening in the adolescent-onset schizophrenia prodrome
[66], only some of the patients described as at risk for
schizophrenia eventually developed schizophrenia. But
still the number needed to prevent could be studied in
the context of a trial, only as McGorry notes if the risk-
balance equation is in the proper direction [67]. At the
moment there is no legal framework for such a type of
preventive intervention and there is relatively little ethi-
cal debate about these issues [68]. In child and adoles-
cent psychiatry the recent debate on early preventive
interventions in the prodromal phase of schizophrenia
might serve as an example [69]. As at the moment there
is no procedure to label medications for preventive
intervention except from vaccines.
When talking about statistically relevant risks to
develop late onset neuropsychiatric diseases no con-
trolled trial can be imagined studying the real outcomes
of an intervention. The current regulations and proce-
dures for clinical trial that are well established are
inadequate in this context [70]. Therefore the identifica-
tion of molecular targets etiologically responsible for the
outcome is important. For surrogate endpoints to be
applicable to preemptive strategies, their predictive
validity both positive and negative relative to distal
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clinical outcomes must to sufficiently robust to be ethi-
cal [71]. It also is unclear, who can make informed deci-
sions about early interventions in children concerning
their adult life. In most legal systems parents are
thought to be best decision makers because usually they
try to consider the best interests of the child, but it is
well known, that in the aim of granting their children
the best possible treatment, parents may act in an over-
protective or over-interventional manner. The ethical
judgement seems to be relatively obvious in monoge-
netic disorders, such as Fragile X syndrome where
MGluR 5 antagonists are promising disease-modifying
therapies [27]. Here a clear diagnosis allows to predict
severe consequences and even if the phenomenology of
the disorder is not yet visible there is a 100% risk for a
later development of the full blown disease. In this con-
text, it is clear that the persons carrying this genetic
information can be called ill at birth or even before
birth and the ethics of treatment discussed rationally in
an ethical context. But what about relative risks, if
screening tests discovers a 30% elevation over the nor-
mal risks to develop a disease like depression? Will par-
ents be able to decide that it is reasonable to intervene
to prevent a relatively smaller risk and even more so
what parents will allow testing of new substances and
concepts in their children? It becomes clear that the
severity of the outcome and the identifiable costs of a
disease, perhaps defined by reduced quality of life years
(QALY) or similar measure, will play an important role
in the ethical judgement. As the field moves toward pre-
emptive interventions, it is our obligation as clinicians
and clinical neuroscientists to introduce and to reinforce
that debate in our discussions with researchers from
fundamental research usually dealing with cells or ani-
mals. As advances in fundamental biology fuel the
development of potentially preemptive interventions for
children by first intent, the discussion of ethical will
need to begin in the preclinical translational space
before compounds enter Phase I and proof-of-concept
trials.
Conclusions
As described in a recent article by the NIMH Director,
Tom Insel, on transforming psychiatry as a clinical disci-
pline [29], the age of symptomatic diagnosis and current
generation treatments is passing; the age of interven-
tions that emerge from the revolution in translational
developmental neuroscience has begun. The twin NIMH
Council workgroup reports on translational develop-
mental neuroscience [5] and interventions research [48],
respectively, which shift the National Institute of Mental
Health away from current generation treatments and
toward early phase clinical pharmacology, presage the
development of just these kind of preemptive
treatments. Because these newer interventions will
emerge from an improved understand of the fundamen-
tal biology of the illnesses, they should be more effective
in patients who are ill and, excitingly, will eventually
become preventive if not preemptive, e.g. they will be
delivered to very young children who are at risk but not
yet showing early signs of mental illness. As a result,
pediatric psychiatry will increasingly become the front
end (the most important end) of a lifespan developmen-
tal model for mental illnesses. More than a little humi-
lity is required as this vision unfolds over the next many
years. For a while, studies in adults will still lead studies
in youth: developing interventions for mentally ill youth
will emerge once the fundamental biology catches up
such that science drives innovation and innovation
drives application in the form of interventions. As part
of this process, biomarkers on the road to stratified and
ultimately personalized medicine will be a key develop-
ment–finally, the age of molecular diagnosis and the
dawn of the age of companion diagnostics to optimize
treatment for psychiatric illness. For the field of pedia-
tric psychopharmacology to thrive it will be important
to embrace and actively participate in this revolution,
including addressing its ethical implications, so that
mentally ill youth are viewed as a key target population
and, consequently, truly preemptive, preventive and
curative interventions will be developed for children by
first intent [1,8,9].
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